Therapy of chronic hepatitis C: Virologic response monitoring

Therapy of chronic hepatitis C: Virologic response monitoring

Blog Article

floor mat alarm for elderly Background/Aim.Virological testing is considered to be essential in the management of hepatitis C virus (HCV) infection in order to diagnose infection, and, most importantly, as a quide for treatment decisions and assess the virological response to antiviral therapy.The aim of this study was to determine the rate of a sustained virological response (SVR) and various factors associated with response rates in chronic hepatitis C infected patients treated with pegiinterferon alpha (PEGINF) and ribavirin (RBV) combination therapy.Methods.A total of 34 patients, treated with PEG-IFN and RBV were studied.

Serum HCV-RNA was measured before the treatment, 12 weeks following the start of the therapy and 6 weeks after the treatment cessation.SVR was defined as undetectable serum HCV-RNA 6 months of post-treatment rab valiance jakke herre follow-up, virologic relapse (VR) as relapse of HCV-RNA during the post-treatment follow-up.Serum HCV-RNA was measured with the Cobas Amplicor test.Results.At the end of post-treatment follow-up 19 (55.

8%) patients demonstrated a SVR.The majority of the patients were genotype 1 (27), and the other were genotype 3 (5 patients) and genotype 4 (2 patients).There was VR in 6 patients 6 months after the therapy.In 9 patients HCV-RNA was positive after 12 weeks.Conclusion.

We demonstrated that patients with chronic HCV infection can be successfully treated with combination of PEG-INF and RBV.This result emphasizes also that post-treatment follow-up to identify patients with SVR or VR could be important.